EPG5

Across TCGA pan-cancer cohorts, EPG5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EPG5 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EPG5 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EPG5 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where EPG5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.427	0.691	.004	32	view →
CCRCC	DFS	Median	All	0.867	0.613	.003	9	view →
UCEC	OS	Quartile	II,III,IV	1.000	0.519	.045	4	view →
LUAD	OS	Median	II,III,IV	1.000	0.807	.010	4	view →
HNSC	OS	Quartile	IV	0.928	0.578	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EPG5–PDAC (OS)

Open the PDAC breakdown →